# A Safety and Tolerability Study of ILB® in Patients With Amyotrophic Lateral Sclerosis (ALS)

> **NCT03705390** · PHASE2 · TERMINATED · sponsor: **University of Birmingham** · enrollment: 11 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- Motor Neuron Disease

## Interventions

- **DRUG:** ILB®

## Key facts

- **NCT ID:** NCT03705390
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-29
- **Primary completion:** 2021-07-28
- **Final completion:** 2021-07-28
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Study initially suspended due to COVID-19 Pandemic- treatment stopped - never reopened to recruitment..
- **Last updated:** 2025-06-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03705390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03705390, "A Safety and Tolerability Study of ILB® in Patients With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03705390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*